Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): A first-in-human randomized, placebo-controlled trial

British Journal of Clinical Pharmacology

Volumn 80, Issue 6, 2015, Pages 1350-1361

  Van Poelgeest, Eveline P ^a   Hodges, Michael R ^b   Moerland, Matthijs ^a   Tessier, Yann ^a   Levin, Arthur A ^b   Persson, Robert ^b   Lindholm, Marie W ^b   Dumong Erichsen, Kamille ^b   Ørum, Henrik ^b   Cohen, Adam F ^a   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b Santaris Pharma AS   (Denmark)

Author keywords

antisense; hypercholesterolaemia; LDL C; PCSK9; SPC5001

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; COMPLEMENT FACTOR; CREATININE; GLUTATHIONE TRANSFERASE ALPHA; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; KEXIN; KIDNEY INJURY MOLECULE 1; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE INHIBITOR; SPC 5001; SUBTILISIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; ANTISENSE THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONCENTRATION PROCESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FIRST IN HUMAN STUDY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERPIGMENTATION; INJECTION SITE REACTION; KIDNEY BIOPSY; MACULOPAPULAR RASH; NEPHROTOXICITY; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN TARGETING; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ATROPHY; SKIN DEFECT; SKIN MANIFESTATION; STEATOSIS; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; FEMALE; KIDNEY; MALE; MIDDLE AGED;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84957434512     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12738     Document Type: Article

References (34)

1. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR,. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26-35.
2. Goldstein JL, Brown MS,. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-8.
3. Nassoury N, Blasiole DA, Tebon OA, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG,. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007; 8: 718-32.
4. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C,. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-6.
5. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL,. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011; 21: 835-43.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH,. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
7. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH,. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37: 161-5.
8. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, Elmen J, Seidah NG, Straarup EM,. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010; 5: e10682.
9. Lindholm MW, Elmen J, Fisker N, Hansen HF, Persson R, Moller MR, Rosenbohm C, Orum H, Straarup EM, Koch T,. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012; 20: 376-81.
10. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M,. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015; 163: 40-51.
11. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El SM, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ,. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
12. Veedu RN, Wengel J,. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 2009; 6: 321-3.
13. van Poelgeest EP, Swart RM, Betjes MG, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, Burggraaf J,. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 2013; 62: 796-800.
14. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A,. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383: 60-8.
15. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA,. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from two randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012; 60: 1888-98.
16. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD,. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18.
17. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH,. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-23.
18. Crooke S,. Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. Boca Raton Florida: CRC Press, 2007.
19. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR,. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694.
20. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST,. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
21. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC,. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-22.
22. Herrington WG, Talbot DC, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, Roberts IS,. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis 2011; 57: 300-3.
23. Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, Sidders B, Corbau R, Pickford C, Murray EJ,. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother 2011; 55: 3105-14.
24. Hildebrandt-Eriksen ES, Aarup V, Persson R, Hansen HF, Munk ME, Orum H,. A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther 2012; 22: 152-61.
25. van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW,. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res 2014; 111: 53-9.
26. Bennett CF, Swayze EE,. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
27. Waring WS, Moonie A,. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila) 2011; 49: 720-8.
28. Lindholm MW,. LNA oligonucleotide in vivo renal screening v2.0 (Poster), DIA/FDA meeting on oligonucleotide therapeutics, Washington, September 2013.
29. Hair P, Cameron F, McKeage K,. Mipomersen sodium: first global approval. Drugs 2013; 73: 487-93.
30. Engelhardt JA,. Predictivity of animal studies for human injection site reactions with parenteral drug products. Exp Toxicol Pathol 2008; 60: 323-7.
31. FDA Briefing Document NDA 203568 Mipomersen Sodium Injection 200 mg/mL (2012). 2015.
32. Frazier KS,. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 2015; 43: 78-89.
33. Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S, Taneja N, O'Shea J, Shaikh S, Zhang L, van der Sluis RJ, Jung ME, Akinc A, Hutabarat R, Kuchimanchi S, Fitzgerald K, Zimmermann T, van Berkel TJ, Maier MA, Rajeev KG, Manoharan M,. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014; 136: 16958-61.
34. Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, Riney S, Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE, Seth PP,. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 2014; 42: 8796-807.